ArticleToxicology2025
Transcriptomic dose response assessment of PFAS chemicals 3:3 fluorotelomer carboxylic acid, 7:3 fluorotelomer alcohol, and perfluorohexanesulfonamide.
Article in Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Per- and polyfluoroalkyl substances (PFAS) are a diverse class of anthropogenic chemicals, and their widespread use in manufacturing and commerce has led to introduction of these chemicals into the environment. Owing to the lack of traditional toxicology data on the majority of PFAS, novel testing methods that provide supporting information to inform human health impacts in a relatively short time frame will be increasingly important. The US Environmental Protection Agency's (EPA) Transcriptomic Assessment Process (ETAP) was recently implemented by the Agency as an efficient and cost-effective method to begin assessing potential human health impacts of chemicals that lack traditional toxicity testing data. The method involves short-term oral dosing in male and female adult rats over a five-day interval, followed by transcriptomic dose-response assessment in twelve tissues to determine a point of departure. The ETAP point of departure identifies the dose at which there are no coordinated transcriptional changes that would indicate a potential toxicity of concern. However, this approach does not explore any specific association with hazard or mechanism. Reported here are ETAP results for three PFAS chemicals: 3:3 fluorotelomer carboxylic acid (3:3 FTCA), 7:3 fluorotelomer alcohol (7:3 FTOH), and perfluorohexanesulfonamide (PFHxSA). The transcriptomic points of departure associated with the tested chemicals, as assessed via ETAP and allometrically scaled to human equivalent doses, were 0.00235 (3:3 FTCA), 0.0152 (7:3 FTOH), and 0.00358 (PFHxSA) mg/kg-day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.